Ubs Group Ag Celcuity Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Celcuity Inc. stock. As of the latest transaction made, Ubs Group Ag holds 73,283 shares of CELC stock, worth $966,602. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,283

Previous 37,645 94.67%

Holding current value

$966,602

Previous $616,000 77.27%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.98 - $19.15 $498,219 - $682,467	35,638 Added 94.67%	73,283 $1.09 Million
Q2 2024 Aug 13, 2024	SELL	$14.1 - $20.78 $164,434 - $242,336	-11,662 Reduced 23.65%	37,645 $616,000
Q1 2024 May 13, 2024	SELL	$13.74 - $21.6 $48,557 - $76,334	-3,534 Reduced 6.69%	49,307 $1.07 Million
Q4 2023 Feb 09, 2024	BUY	$8.7 - $15.02 $346,460 - $598,141	39,823 Added 305.91%	52,841 $769,000
Q3 2023 Nov 09, 2023	SELL	$8.96 - $10.75 $3,118 - $3,741	-348 Reduced 2.6%	13,018 $118,000
Q2 2023 Aug 11, 2023	BUY	$9.39 - $12.18 $78,143 - $101,361	8,322 Added 164.99%	13,366 $146,000
Q1 2023 May 12, 2023	SELL	$9.4 - $12.82 $601 - $820	-64 Reduced 1.25%	5,044 $51,000
Q4 2022 Feb 08, 2023	BUY	$7.55 - $14.01 $5,836 - $10,829	773 Added 17.83%	5,108 $71,000
Q3 2022 Nov 10, 2022	SELL	$8.0 - $10.64 $7,816 - $10,395	-977 Reduced 18.39%	4,335 $44,000
Q2 2022 Aug 10, 2022	SELL	$5.35 - $10.11 $8,897 - $16,812	-1,663 Reduced 23.84%	5,312 $48,000
Q1 2022 May 16, 2022	SELL	$7.93 - $13.33 $238,161 - $400,339	-30,033 Reduced 81.15%	6,975 $65,000
Q4 2021 Feb 14, 2022	BUY	$11.96 - $19.35 $40,819 - $66,041	3,413 Added 10.16%	37,008 $488,000
Q3 2021 Nov 15, 2021	BUY	$17.35 - $24.87 $62,008 - $88,885	3,574 Added 11.9%	33,595 $605,000
Q2 2021 Aug 13, 2021	SELL	$14.25 - $30.93 $3,363 - $7,299	-236 Reduced 0.78%	30,021 $721,000
Q1 2021 May 12, 2021	BUY	$10.43 - $17.8 $41,448 - $70,737	3,974 Added 15.12%	30,257 $434,000
Q4 2020 Feb 11, 2021	BUY	$5.13 - $11.72 $32,231 - $73,636	6,283 Added 31.42%	26,283 $241,000
Q2 2020 Jul 31, 2020	SELL	$4.42 - $11.04 $13,061 - $32,623	-2,955 Reduced 12.87%	20,000 $139,000
Q1 2020 May 01, 2020	BUY	$5.79 - $11.78 $88,031 - $179,103	15,204 Added 196.16%	22,955 $149,000
Q4 2019 Feb 14, 2020	SELL	$9.47 - $16.71 $162,202 - $286,208	-17,128 Reduced 68.85%	7,751 $82,000
Q3 2019 Nov 14, 2019	BUY	$15.74 - $23.65 $73,112 - $109,854	4,645 Added 22.96%	24,879 $423,000
Q2 2019 Aug 14, 2019	SELL	$19.88 - $25.0 $16,321 - $20,525	-821 Reduced 3.9%	20,234 $506,000
Q1 2019 May 14, 2019	BUY	$18.38 - $24.44 $68,539 - $91,136	3,729 Added 21.52%	21,055 $461,000
Q4 2018 Feb 14, 2019	BUY	$20.87 - $29.05 $19,743 - $27,481	946 Added 5.78%	17,326 $416,000
Q3 2018 Nov 14, 2018	BUY	$20.96 - $30.77 $14,085 - $20,677	672 Added 4.28%	16,380 $471,000
Q2 2018 Aug 14, 2018	BUY	$16.13 - $26.99 $230,852 - $386,280	14,312 Added 1025.21%	15,708 $390,000
Q1 2018 May 15, 2018	BUY	$13.55 - $21.3 $11,490 - $18,062	848 Added 154.74%	1,396 $23,000
Q4 2017 Feb 14, 2018	BUY	$12.12 - $21.65 $1,102 - $1,970	91 Added 19.91%	548 $10,000
Q3 2017 Nov 14, 2017	BUY	$11.94 - $14.29 $5,456 - $6,530	457	457 $6,000

Others Institutions Holding CELC

# of Institutions

107

Shares Held

30.3M

Call Options Held

30.8K

Put Options Held

152K

View Full List

About Celcuity Inc.

Ticker CELC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,941,300
Market Cap $197M
Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...

More about CELC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account